



## **Pandemics-Born Revolution in the Preclinical and Clinical Trials of Microbial Vaccines**

Guest Editors:

**Dr. Maria G. Isaguliantis**

**Prof. Dr. Felicity Jane Burt**

**Dr. Ilya Gordeychuk**

Deadline for manuscript  
submissions:  
**closed (31 August 2023)**

### **Message from the Guest Editors**

This issue is welcoming submissions of experimental papers, short communications, reviews and activity reports focusing on the above problems. We specifically welcome submissions which consider the impact of SARS-CoV-2 pandemics on:

- Development of plug and play platforms approach
- Future vaccine discovery/development; harnessing the current momentum for vaccine development to create new vaccine platforms
- Novel vaccines/technologies for accommodating emerging SARS-CoV-2 variants
- Novel vaccines/technologies against other common and emerging (re-emerging) pathogens
- Development of animal models to test vaccine efficacy
- Vaccine manufacture and upscale in the future
- Formulations that aid the stability of vaccines facilitating distribution to less accessible and low resource countries





an Open Access Journal by MDPI

## Editor-in-Chief

### **Prof. Dr. Ralph A. Tripp**

Department of Infectious  
Diseases, College of Veterinary  
Medicine, University of Georgia,  
Athens, GA 30602-7387, USA

## Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

## Author Benefits

**Open Access:** free for readers, with **article processing charges (APC)** paid by authors or their institutions.

**High Visibility:** indexed within **Scopus**, **SCIE (Web of Science)**, **PubMed**, **PMC**, **Embase**, **CAPLus / SciFinder**, and **other databases**.

**Journal Rank:** JCR - Q2 (Medicine, Research and Experimental) / CiteScore - Q1 (Pharmacology (medical))

## Contact Us

*Vaccines* Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/vaccines](http://mdpi.com/journal/vaccines)  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)  
[X@Vaccines\\_MDPI](https://twitter.com/Vaccines_MDPI)